Immunic, Inc. (IMUX): Capital Expenditures
$161.0K
Year ended 2025-12-31
$329.0K
Trailing 12 months to 2026-06-30
+12.9%
3-year compound annual growth
+2.0%
5-year compound annual growth
-23.5%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $161.0K | -39.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $264.0K | -21.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $334.0K | +198.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $112.0K | +67.2% | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | $67.0K | -54.1% | 2023-02-23, From 2021-01-01 |
| 2020-12-31 | $146.0K | +165.5% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $55.0K | +71.9% | 2021-02-26, From 2019-01-01 |
| 2018-12-31 | $32.0K | -95.3% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $685.0K | +23.2% | 2019-03-04, From 2017-01-01 |
| 2016-12-31 | $556.0K | -76.2% | 2019-03-04, From 2016-01-01 |
| 2015-12-31 | $2.34M | +66.1% | 2018-03-13, From 2015-01-01 |
| 2014-12-31 | $1.41M | -5.1% | 2017-03-07, From 2014-01-01 |
| 2013-12-31 | $1.48M | +468.6% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $261.0K | n/a | 2015-03-20, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Immunic, Inc. (IMUX) | 2025-12-31 | $161.0K | -39.0% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $110.8K | n/m |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $0 | -100.0% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $191.0K | -65.5% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $28.5K | +762.8% |
| Faeth Therapeutics, Inc. (FTH) | 2025-12-31 | $16.0K | -89.0% |
| Gain Therapeutics, Inc. (GANX) | 2024-12-31 | $22.5K | +46.5% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $16.0K | -92.8% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $16.0K | -81.6% |
Compare IMUX, KPRX, HCWB, INBP side by side · Screen every company in Pharmaceutical Preparations ↗